CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Stopped early

Conditions studied: Crohn's Disease

In brief

The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective of this study in this study population is to evaluate disease severity over time in participants with CD treated with natalizumab based on changes in the Harvey-Bradshaw Index (HBI).

Key facts

Study ID
NCT00707512
Run by
Biogen
People needed
87
Starts
2008-06-30
Expected to finish
2015-05-28
Last updated by the study team
2024-06-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.